Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACHIEVE: HM15136 in Pediatric Congenital Hyperinsulinism
2024-515290-98-00Phase 2Authorised
- Sponsor
- Hanmi Pharmaceutical
- Start
- Jul 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of efpegerglucagon in congenital hyperinsulinism (HI), sponsored by Hanmi Pharmaceutical. Primary endpoints: Incidence of adverse events, treatment-emergent adverse events, and serious adverse events, Incidence of clinical laboratory abnormalities and 12 more. Planned start Jul 2024; status: authorised.
02
Drugs
efpegerglucagon
03
Conditions
congenital hyperinsulinism (HI)
Beyond the preview
Go deeper on 2024-515290-98-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515290-98-00.